Dendrogenix, an innovative biotechnology company based in Liège (Belgium) announced today positive results from its first Phase 1 clinical trial evaluating its drug candidate DX243. Building on these encouraging data, the company plans to initiate a Phase 2a clinical trial in the first quarter of 2026 in the field of age-related hearing loss (presbycusis).
Located at the heart of the biomedical research ecosystem of CHU Sart-Tilman and GIGA Neuroscience, Dendrogenix is developing a novel proprietary class of compounds called “Dendrogenin”, with DX243 as its first clinical candidate. These compounds are intended for the treatment of neurodegenerative diseases, with a particular focus on age-related auditory disorders.
Phase 1 clinical results: excellent tolerability supporting ...